Nivolumab/cabozantinib shows improvements in long-term survival for RCC

Press/Media

Period	19 Feb 2023

Media coverage

Title	Nivolumab/cabozantinib shows improvements in long-term survival for RCC
Media name/outlet	Urology Times
Country/Territory	United States
Date	19/02/23
URL	ct.moreover.com/?a=50051495867&p=1gw&v=1&x=kRs936uE1MstnfO0jTZsBQ
Persons	Mauricio Burotto

Title	Nivolumab Plus Cabozantinib Shows Sustained Survival Advantage in Advanced RCC
Media name/outlet	OncLive
Country/Territory	United States
Date	19/02/23
URL	ct.moreover.com/?a=50051683500&p=1gw&v=1&x=br4DPLMuFfGS995jT9oy6A
Persons	Mauricio Burotto